Statistics
Publications
57
Citations
40.3K
H-Index
39
Active since
2001
Christopher Harbison is an author at Bristol-Myers Squibb (United States) specializing in oncology, medicine, and cancer immunotherapy.
Publications per year
2001–2021
57
57
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder, Vladimir Makarov, Taha Merghoub et al. · New England Journal of Medicine · 2014 · 4.4K citations · Full text
Medicine, Immunology, Oncology +17
Transcriptional Regulatory Networks in <i>Saccharomyces cerevisiae</i>
Tong Ihn Lee, Nicola J. Rinaldi, François Robert et al. · Science · 2002 · 3K citations
Transcriptional regulatory code of a eukaryotic genome
Christopher Harbison, D. Benjamin Gordon, Tong Ihn Lee et al. · Nature · 2004 · 2.2K citations · Full text
1–5 of 57